Fairmount Funds Management LLC

Fairmount Funds Management LLC has filed trades across 10 companies (mainly through SEC (Form 4)), most often in Apogee Therapeutics, Inc., Cogent Biosciences, Inc. and Dianthus Therapeutics, Inc. /DE/. Over a trading history stretching from 21 September 2021 to 3 September 2026, the count stands at 48 filings.

The open-market side counts 17 purchases for €139.1M alongside 4 sales for €433.2M. The totals do not cover 1 filing with an undisclosed amount. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Outside the open market, there are 5 share grants and 7 option exercises. 2026 to date brings 2 purchases and 4 sales.

A typical purchase (the median) is worth €8.6M. Of 17 purchases, 5 formed part of a group of insiders buying within 30 days of each other. Such overlaps are known as a cluster signal: distinct people reaching the same decision at about the same time.

Most recently, on 3 September 2026, the filings show a transaction in Apogee Therapeutics, Inc. The latest purchase dates back some time: it was published 89 days ago, on 20 July 2026. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. US insiders must file a Form 4 within two business days of a trade. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.